Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat for VHL-associated Hemangioblastomas
NCT02108002Phase 1Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Apr 2014
- Primary completion
- Sep 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorinostat in von Hippel–Lindau disease (VHL) and hemangioblastoma, sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: The presence and quantity of mutant VHL protein in resected hemangioblastoma specimens at 7 days. Started Apr 2014; status: completed.
02
Drugs
vorinostat
03
Conditions
von Hippel–Lindau disease (VHL)hemangioblastoma
Beyond the preview
Go deeper on NCT02108002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108002.